Vedanta Biosciences has “significantly reduced” its headcount to channel its remaining resources to its lead live bacteria ...

The leaders of Chugai Pharmaceutical are tired of their company not getting its due. At the J.P. | The leaders of Chugai ...

Hopes were high Wednesday for a billion-dollar megadeal—the kind the J.P. Morgan Healthcare Conference is known for—but no ...

Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...

Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Boston Scientific is capping off a busy week with a major buyout, entering a deal worth about $14.5 billion to acquire ...

The J.P. Morgan Healthcare Conference, as well as Fierce's own JPM Week, roll into Wednesday with plenty more events, ...

It’s been a subdued—albeit sunny—start to healthcare’s biggest conference in San Francisco. | It’s been a subdued—albeit ...

Looking to usher in a more “predictable” year in 2026, Illumina is working with officials in China as it remains on the ...

The bispecific antibody—which targets the IL-23p19 and TL1A pathways—was licensed from China’s Qyuns Therapeutics. Since ...

Charles River Laboratories has struck a $510 million deal to buy a non-human primate provider, furthering efforts to ...